Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBE

Award Number: R01CA266467
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBE - Project Summary Current proton and ion therapy treatment planning procedures utilize either the physical quantity linear energy transfer (LET) as a surrogate for biological effectiveness or make use of relative biological effectiveness (RBE) models that convert absorbed dose to biologically weighted dose, assumed to be iso- effective to photons. LET is indeed important clinically for planning treatments with charged particles, but there are known problems. Ion beams with the same LET can have different RBE, depending on particle type and energy. Therefore, LET by itself is not an ideal parameter to use in radiation treatment planning (RTP). For clinical application of carbon therapy, RBE-models have been developed. However, comparisons of different RBE models used for carbon therapy have shown that dose prescriptions implemented with the European local effect model or the Japanese National Institute of Radiological Sciences mixed beam model can be up to 15% different. We use the term ionization detail (ID) to mean the detailed distribution of ionizing events along a particle track on the nanometer scale. Our chief hypothesis, which is supported by strong prior evidence, is that ID can predict, better than LET and existing RBE models, the biological effects associated with high-LET radiation. We have previously shown how ID can be used together with these models to improve their performance, providing a path for integrating ID-based RTP into clinical practice. Our approach could lead to a consensus in proton and ion therapy RTP. With four Specific Aims, we have chosen a translational and stepwise approach to build an ID-based prediction model. We will test this model for different endpoints and model systems ranging from in vitro cell and molecular data, obtained by irradiating human cancer cells in flasks and anatomical phantoms, to in vivo mice/human tumor data. We will develop advanced algorithms and computational GPU- based methods and use them for effective inverse treatment planning with actively scanned proton and ion beams. This technology will be applied to demonstrate the practicality and evaluate the clinical efficacy of our approach in prostate and chordoma treatments, first prospectively in human-size pelvis and head phantoms, and finally, retrospectively in patients treated for these diseases. We have assembled a strong team with the complementary expertise needed for this project. Members of our team have all successfully collaborated together. Upon completion, we will provide a rigorously tested and validated approach to ID-based particle RTP that will be available for cross-correlation with existing clinical data and for careful testing in prospective clinical particle therapy trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $595,665 )
2026	2026	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Treatment Research	000	5	9/1/2026	NON-COMPETING CONTINUATION	$595,665
														Subtotal = $595,665

Issue Date FY: 2025 ( Subtotal = $595,574 )
2025	2025	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Treatment Research	000	4	9/3/2025	NON-COMPETING CONTINUATION	$595,574
														Subtotal = $595,574

Issue Date FY: 2024 ( Subtotal = $566,612 )
2024	2024	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94103	SAN FRANCISCO	USA	Cancer Treatment Research	000	3	9/3/2024	NON-COMPETING CONTINUATION	$566,612
														Subtotal = $566,612

Issue Date FY: 2023 ( Subtotal = $581,657 )
2023	2023	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Treatment Research	000	2	8/28/2023	NON-COMPETING CONTINUATION	$581,657
														Subtotal = $581,657

Issue Date FY: 2022 ( Subtotal = $690,634 )
2022	2022	REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE	1855 FOLSOM ST STE 425	SAN FRANCISCO	CA	94143	SAN FRANCISCO	USA	Cancer Treatment Research	000	1	8/23/2022	NEW	$690,634
														Subtotal = $690,634

Grand Total All Awards = $3,030,142

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ionization Detail - Biologically based treatment planning for particle therapy beyond LET-RBE

Award Number: R01CA266467

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer